Unknown

Dataset Information

0

Association between advanced NSCLC T790 M EGFR-TKI secondary resistance and prognosis: A observational study.


ABSTRACT: Epidermal growth factor receptor (EGFR) mutations for EGFR-tyrosine kinase inhibitors (EGFR-TKI) in non-small cell lung cancer (NSCLC) patients are with clinical benefits. Nevertheless, eventual resistance to EGFR-TKI is almost inevitable. In about 50% patients, EGFR-TKI develops a secondary mutation, which is often the T790?M mutation. We aimed to investigate the relationship between EGFR gene status in the peripheral blood and prognosis (progression-free survival [PFS] and overall survival [OS]) in advanced lung adenocarcinoma patients and the 20 exon 790 site mutation (T790?M) and acquired resistance to EGFR-TKI.A total of 49 patients with EGFR-TKI resistance and advanced lung cancer who visited the Shihezi University School of Medicine between 12/2013 and 12/2014 were enrolled in this study. Peripheral blood plasma DNA was isolated after EGFR-TKI resistance and the EGFR exon 20 T790?M mutation was detected using the probe amplification refractory mutation system method.The T790?M mutation rate was 30.6% (15/49). There was no association between T790?M mutation and age, gender, smoking, clinical stage, Eastern Cooperative Oncology Group rating, initial EGFR mutation, and EGFR-TKI drugs, but EGFR-TKI resistance was associated with progression (P?=?.009). Median progression-free survival (PFS) of patients with T790?M mutation was 9.6 months and median overall survival (OS) was 17.6 months, compared to 6.8 and 12.7 months in controls (P?=?.018 and P?=?.027). Multivariate analysis showed that T790?M mutations independently affected the PFS (risk ratio, RR?=?0.653, 95% confidence interval, CI: 0.069-0.886, P?=?.032) and OS (RR?=?0.847, 95% CI: 0.208-2.696, P?=?.008).T790?M mutation and EGFR-TKI resistance are independent factors to affect PFS and OS of non-small cell lung cancer patients.

SUBMITTER: Wang Y 

PROVIDER: S-EPMC6076133 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Association between advanced NSCLC T790 M EGFR-TKI secondary resistance and prognosis: A observational study.

Wang Yuli Y   Wei Yuan Y   Ma Xiaoping X   Ma Xinyu X   Gong Ping P  

Medicine 20180701 28


Epidermal growth factor receptor (EGFR) mutations for EGFR-tyrosine kinase inhibitors (EGFR-TKI) in non-small cell lung cancer (NSCLC) patients are with clinical benefits. Nevertheless, eventual resistance to EGFR-TKI is almost inevitable. In about 50% patients, EGFR-TKI develops a secondary mutation, which is often the T790 M mutation. We aimed to investigate the relationship between EGFR gene status in the peripheral blood and prognosis (progression-free survival [PFS] and overall survival [OS  ...[more]

Similar Datasets

| S-EPMC4163608 | biostudies-literature
| S-EPMC6726998 | biostudies-literature
| S-EPMC6798878 | biostudies-literature
2017-05-23 | GSE99143 | GEO
| S-EPMC6297127 | biostudies-literature
| S-EPMC6848259 | biostudies-literature